Zydus Launches World's First Opdivo Biosimilar 'Tishtha' in India, Slashes Cancer Treatment Costs

• Zydus Lifesciences introduced Tishtha, the world's first biosimilar of nivolumab, in India on January 22.
• Tishtha is priced at nearly a quarter of Bristol Myers Squibb's original Opdivo, making advanced cancer immunotherapy more affordable.
• Nivolumab is a crucial PD-1 immune checkpoint inhibitor used for various cancers like lung, melanoma, kidney, and Hodgkin lymphoma.
• The biosimilar aims to address affordability, consistency, and long-term availability challenges, benefiting over five lakh cancer patients.
• Developed and manufactured in India, Tishtha ensures supply continuity and is available in 100 mg (Rs 28,950) and 40 mg (Rs 13,950) strengths.

Why It Matters: Zydus's Tishtha biosimilar significantly reduces the cost of nivolumab, expanding access to vital cancer immunotherapy in India.